Patent · US Active

Polymorph form II of tanaproget

US7759341B2 · kind B2 · utility

6Cited by
1References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 26, 2006
Grant dateJul 20, 2010
Priority date—
Expiry dateSep 5, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D265/18
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.